This invention describes a bioerodible fibrin material which is obtained by
mixing fibrinogen and thrombin reconstituted or diluted with a particular high
tonic strength medium, free of calcium. Such a fibrin-based biomaterial develops
a tight structure with thin fibers and small pore size suitable for use as an anti-adhesion
barrier. In this invention, thrombin is no longer the variable which governs the
tightness and the porosity of the fibrin material obtained, but still controls
the clotting time. The mechanical behavior, high-water capacity, and releasable
retention properties for therapeutic agents of this fibrin structure causes the
fibrin material to be ideally suited for use as a drug delivery device, capable
of delivering proteins, hormones, enzymes, antibiotics, antineoplastic agents and
even cells for local and systemic treatment of human and non-human patients.